Everest Joins Race to Make mRNA Covid Vaccines for China
Company’s move comes as Beijing shows growing signs of approving the new type of high-tech vaccination Key takeaways: Everest will pay up to $150 million or more to potentially bring…
Recent Articles
RELATED ARTICLES
- China’s mRNA pioneer Stemirna faces post-Covid reinvention test
-
With healthier finances, Clover Bio shifts to flu and RSV vaccines
2197.HK
- Health Guard plans dual listing to fund HPV vaccine fight
-
Everest reaches new heights on growing drug sales
1952.HK
-
Fosun Pharma, CanSino take different paths as Covid lift fade
2196.HK 6185.HK
-
FAST NEWS: Everest Medicines gets new drug license from Kezar Life
1952.HK
-
FAST NEWS: CanSino’s revenue plunges as demand dries up for Covid vaccines
6185.HK 688185.SHG
Discover hidden China stock gems in our weekly newsletter